The Centers for Medicare & Medicaid Services (CMS) announced a significant change in its reimbursement policy under the CY 2025 Hospital Outpatient Prospective Payment System (HOPPS), effective January 1, 2025. CMS will now unbundle payments for diagnostic radiopharmaceuticals that exceed a per-day cost of $630, allowing these to be reimbursed separately rather than bundled with supplies. This change is expected to improve access to nuclear medicine scans for patients, as noted by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), which advocated for this adjustment. The decision eliminates the need for legislative action under the FIND Act for reimbursement improvements. Several radiopharmaceutical companies welcomed the move, indicating it could enhance access to advanced imaging agents for patients. SNMMI plans to collaborate with CMS to further refine reimbursement models to promote equitable access to care.
Tue, 05 Nov 2024 19:05:44 GMT | Urology Times